Clinical Features and Therapeutic Efficacy in Adult Acute Lymphoblastic Leukemia with t (1; 19) (E2A-PBX1).
- Author:
Kai-Qi LIU
1
;
Xiao-Yuan GONG
1
;
Xing-Li ZHAO
1
;
Hui WEI
1
;
Ying WANG
1
;
Dong LIN
1
;
Chun-Lin ZHOU
1
;
Bing-Cheng LIU
1
;
Hui-Jun WANG
1
;
Cheng-Wen LI
1
;
Qing-Hua LI
1
;
Ben-Fa GONG
1
;
Yan LI
1
;
Yun-Tao LIU
1
;
Ying-Chang MI
1
;
Jian-Xiang WANG
2
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Homeodomain Proteins; genetics; Humans; Immunophenotyping; Oncogene Proteins, Fusion; genetics; Precursor Cell Lymphoblastic Leukemia-Lymphoma; genetics; therapy; Recurrence; Remission Induction
- From: Journal of Experimental Hematology 2019;27(3):637-640
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the clinical features and therapeutic efficacy in adult ALL patients with t (1; 19) (E2A-PBX1).
METHODS:The clinic data of 19 adult ALL patients with t (1; 19) (E2A-PBX1) in our hospital from Nov. 22, 2010 to Apr. 4, 2018 were collected. The clinical features,complete remission (CR) rate, overall survival (OS) rate and relapse-free survival (RFS) rate of patients received chemotherapy and chemotherapy+HSCT were analyzed.
RESULTS:In all the 19 patients, the median age was 24 (14-66), median WBC count was 16.47×109 (1.8-170.34)/L, median Hb level was 98 (65-176) g/L, median Plt count was 50 (15-254)×109/L. Pre B-ALL were 17 cases (89.5%), and common B-ALL were 2 cases (10.5%). Patients received the induction therapy, the overall CR rate was 94.7%, one course CR rate was 94.7%, 4 year OS rate was 47.1% and RFS rate was 43.3%. The OS rate and RFS rate of patients received transplantation were slightly higher than those of patients not received transplantation (OS: 62.5% vs 36.7%) (P=0.188)；RFS (62.5% vs 38.9%) (P=0.166).
CONCLUSION:Most adult ALL patients with t (1; 19) (E2A-PBX1) is Pre B-ALL by Immunophenotyping, as compared with the pediatric patients, the therapeutic efficacy for adult patients with t (1; 19) (E2A-PBX1) is worsen, therefore, stem cell transplantation is still acquired for better long term survival.
